AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

As a writer, I often stare into oblivion, hoping that some idea comes flying out of the blue, penetrates my mind and speaks: “This is it! The Jackpot! You’re really gonna knock ‘em dead with this one!

Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.

Three Motley Fool contributors think they've found ideal dividend growth stocks to buy and hold -- and all three are ...

Healthcare giants AbbVie and Abbott Laboratories are both Dividend Kings. They should maintain their dividend growth habits ...

The author includes U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull ...

Upadacitinib 15 mg — but not 7.5 mg — alongside a glucocorticoid taper demonstrated superior efficacy to placebo with a ...

AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 ...

The pharmaceutical industry spends a ton of money on drug ads. This should come as no surprise to anyone who watches TV or ...